Regenexx Team Publishes New Tendon PRP Paper!

By /

Knowing how to dose orthobiologics, like PRP, is critical. However, we have very little published data, and physicians use different machines that produce different types of PRP at different doses. So to say that orthobiologics as a field is one big mess is an understatement. The Regenexx research team has been working to clean up that mess for many years. Our most recent entry in that effort is a new tendon PRP research paper on tendons and PRP dosing.

Why Spend This Money?

Very few orthobiologics companies spend money on research. Even fewer physician networks even have lab research capabilities in the first place, and none so far have spent their own money on lab research to support correct dosing. For Regenexx, publishing this most recent paper cost six figures in hard costs for lab items, employee time, and my time. Why do this?

As someone once said, it’s lead, follow, or get out of the way. This paper is all about leading the orthobiologics space. In this case, there was confusion on how to properly dose tendon injuries with platelet-rich plasma. Some papers went one way, and other papers (which were poorly done) went the other direction. So there needed to be a well-done tiebreaker paper that sided with one or the other approach.

Join us for a free Regenexx webinar.

What Is PRP?

Platelet-rich plasma (PRP) is made by taking a blood sample from the patient and concentrating the platelets in that blood. Platelets contain many helpful growth factors that can act like an espresso shot for the local repair cells that help heal damage. There are different types of PRP, and of those commonly injected, there is leukocyte-rich (red) and leukocyte-poor (amber).

Approaches to PRP Dosing

The problem with bedside PRP machines is that they generally are only validated to produce one type of PRP and at one dose. In PRP shots, the dose is commonly reported as either a certain number of platelets or a times concentration over baseline. More platelets in the PRP have more growth factors and thus should, at face value, produce better clinical results.

The issue of “more is better” in PRP dosing has been hotly debated for years. The problem is that what often enters into the equation are white papers and other lower-level research investigations pushed by manufacturers of specific machines that all seem to show that whatever that machine produces is the best thing since sliced bread. This is because the manufacturers of these machines are often locked into producing only one type and dose of PRP.

We at Regenexx have always used a flexible lab platform, which means that we can produce any type or concentration of PRP. So our guidelines for dosing have always been driven by what we see in the lab. For example, we noticed early on that higher platelet concentrations sparked more growth in older mesenchymal stem cells (MSCs) in culture. This was the case for older cells, with younger cells tending to max out their proliferation at lower PRP doses. Hence, we have always used higher PRP doses in older patients.

Is High or Low Concentration Better for Tendons?

Based on our experience with MSCs in culture, we have always gone with higher doses in tendon injections to treat tears or degeneration (tendinopathy). The literature generally supported that approach until a paper was published that seemed to show that higher PRP doses in tendons caused less and not more tendon cell healing. The results of this paper generally didn’t fit with what we saw clinically. Why? Many of our tendon injury patients were doing well getting very high-dose platelet injections. So we dug into the new paper, and our scientific team saw a fatal flaw. To understand what that was, see my video below:

Join us for a free Regenexx webinar.

Our New Tendon PRP Research

In our new study, we took human tendon cells (tenocytes) and tested both their growth rate (proliferation) and ability to close an experimental wound (scratch test) relative to the dose of platelets used. We also used older tendon cells because older patients typically present to us with tendinopathy. We also fixed the experimental design flaws of the paper discussed above. What did we find?

There is a direct dose-response relationship. This means the higher we went on platelet dose the more tendon cell proliferation we saw and the better the cells were at healing the experimental wound. This fits well with our prior observations.

Why do we see a direct dose-response with old cells, and young cells tend to max out their activity with lower platelet doses? It’s likely that old cells, which live in a growth factor (GF) poor environment, have more GF receptors on their surfaces to take advantage of their world. When we then put in higher GF levels with more platelets, these older cells have more receptor hits; hence, the cells are more stimulated.

The upshot? At the end of the day, at Regenexx we lead orthobiologics, even if that means spending lots of our own money to figure out the likely best dose for tendons and to correct the scientific record after a poorly constructed study is published. Again, it’s lead, follow, or get out of the way!

Chris Centeno, MD is a specialist in regenerative medicine and the new field of Interventional Orthopedics. Centeno pioneered orthopedic stem cell procedures in 2005 and is responsible for a large amount of the published research on stem cell use for orthopedic applications. View Profile

If you have questions or comments about this blog post, please email us at [email protected]

NOTE: This blog post provides general information to help the reader better understand regenerative medicine, musculoskeletal health, and related subjects. All content provided in this blog, website, or any linked materials, including text, graphics, images, patient profiles, outcomes, and information, are not intended and should not be considered or used as a substitute for medical advice, diagnosis, or treatment. Please always consult with a professional and certified healthcare provider to discuss if a treatment is right for you.

Get Blog Updates by Email

We do not sell, or share your information to third party vendors.

By submitting the form you agree that you’ve read and consent to our Privacy Policy. We may use email, phone, or other electronic means to communicate information about Regenexx.

We will provide information to help you decide whether you want to schedule an evaluation with a Regenexx Physician.

Insurance typically covers evaluations and diagnostic testing (if recommended). Most insurance plans currently do not cover Regenexx Procedures.

Copyright © Regenexx 2021. All rights reserved.



9035 Wadsworth Pkwy #1000
Westminster, CO 80021


*DISCLAIMER: Like all medical procedures, Regenexx® Procedures have a success and failure rate. Patient reviews and testimonials on this site should not be interpreted as a statement on the effectiveness of our treatments for anyone else.

Providers listed on the Regenexx website are for informational purposes only and are not a recommendation from Regenexx for a specific provider or a guarantee of the outcome of any treatment you receive.